Search

Your search keyword '"Rampal, Raajit"' showing total 122 results

Search Constraints

Start Over You searched for: Author "Rampal, Raajit" Remove constraint Author: "Rampal, Raajit" Publisher elsevier inc. Remove constraint Publisher: elsevier inc.
122 results on '"Rampal, Raajit"'

Search Results

1. Treatment approach and outcomes of patients with accelerated/blast-phase myeloproliferative neoplasms in the current era

2. Phase 2 study of add-on parsaclisib for patients with myelofibrosis and suboptimal response to ruxolitinib: final results

4. Interaction between myelodysplasia-related gene mutations and ontogeny in acute myeloid leukemia

5. CXCL8/CXCR2 signaling mediates bone marrow fibrosis and is a therapeutic target in myelofibrosis

7. Role of allogeneic transplantation in chronic myelomonocytic leukemia: an international collaborative analysis

9. A randomized phase 3 trial of interferon-α vs hydroxyurea in polycythemia vera and essential thrombocythemia

10. HMGA1 chromatin regulators induce transcriptional networks involved in GATA2 and proliferation during MPN progression

11. Plasmacytoid dendritic cell expansion defines a distinct subset of RUNX1-mutated acute myeloid leukemia

12. Determining the recommended dose of pacritinib: results from the PAC203 dose-finding trial in advanced myelofibrosis

13. Transient expansion of TP53 mutated clones in polycythemia vera patients treated with idasanutlin

14. Phase 2 study of ruxolitinib and decitabine in patients with myeloproliferative neoplasm in accelerated and blast phase

15. Survival following allogeneic transplant in patients with myelofibrosis

17. Proposals for revised International Working Group–European LeukemiaNet criteria for anemia response in myelofibrosis

18. Pegylated interferon alfa-2a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyurea

21. Impact of High-Molecular-Risk Mutations on Transplantation Outcomes in Patients with Myelofibrosis

22. Jak2V617F and Dnmt3a loss cooperate to induce myelofibrosis through activated enhancer-driven inflammation

23. MPN-375 BET Inhibitor Pelabresib (CPI-0610) Combined With Ruxolitinib in Patients With Myelofibrosis – JAK Inhibitor-Naïe or With Suboptimal Response to Ruxolitinib – Preliminary Data From the MANIFEST Study

25. MPN-075 Efficacy and Safety of Add-on Parsaclisib to Ruxolitinib Therapy in Myelofibrosis Patients With Low Versus Higher Baseline Platelet Counts: A Subgroup Analysis of Data From a Phase 2 Study

27. High prevalence of myeloid neoplasms in adults with non–Langerhans cell histiocytosis

29. Integrated genomic DNA/RNA profiling of hematologic malignancies in the clinical setting

32. North American Blastic Plasmacytoid Dendritic Cell Neoplasm Consortium: position on standards of care and areas of need

35. MPN-136 Pelabresib Plus Ruxolitinib Combination Therapy in JAK Inhibitor-Naïve Patients With Myelofibrosis in the Phase 3 MANIFEST-2 Study: Preliminary Evidence of Bone Marrow Recovery

39. MPN-135 Safety and Efficacy of Pelabresib in Combination With Ruxolitinib for JAK Inhibitor-Naïve Patients With Myelofibrosis: Latest Data From the Phase 3 MANIFEST-2 Study

41. Pelabresib Plus Ruxolitinib Combination Therapy in JAK Inhibitor-Naïve Patients With Myelofibrosis in the Phase 3 MANIFEST-2 Study: Preliminary Evidence of Bone Marrow Recovery

42. Safety and Efficacy of Pelabresib in Combination With Ruxolitinib for JAK Inhibitor-Naïve Patients With Myelofibrosis: Latest Data From the Phase 3 MANIFEST-2 Study

46. Improvement in Individual Symptoms and Total Symptom Score (TSS) and Matching-Adjusted Indirect Comparison (MAIC) Analysis to Compare TSS As a Continuous Endpoint in Patients with Myelofibrosis Treated with Pelabresib in Combination with Ruxolitinib Versus Janus Kinase Inhibitor Monotherapy

50. Erythroid and Megakaryocytic Differentiation Program in JAK2-Mutated Acute Myeloid Leukemia with or without Antecedent Myeloproliferative Neoplasm

Catalog

Books, media, physical & digital resources